Gainwell Technologies, the Medicaid Single PBM (SPBM), announced effective April 1 brand Suboxone will transition to non-preferred status and will require Prior Authorization (PA). Generic buprenorphine/naloxone will remain Preferred (No PA Required). The announcement further encouraged pharmacies to ensure they have advance supplies of the preferred product to manage this utilization shift without patient interruption.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.